Arrowhead Pharmaceuticals Toekomstige groei
Future criteriumcontroles 2/6
Arrowhead Pharmaceuticals zal naar verwachting groeien in winst en omzet met respectievelijk 42.7% en 29.7% per jaar. De winst per aandeel zal naar verwachting groeien met 41.9% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -48.8% zijn.
Belangrijke informatie
42.7%
Groei van de winst
41.87%
Groei van de winst per aandeel
| Biotechs winstgroei | 27.2% |
| Inkomstengroei | 29.7% |
| Toekomstig rendement op eigen vermogen | -48.79% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 06 Aug 2026 |
Recente toekomstige groei-updates
Recent updates
Narratiefupdate • Aug 19
ARWR: SHTG Phase 3 Success And PRV Use Will Drive Future Upside
Arrowhead Pharmaceuticals' updated analyst price target has moved from about $89 to about $110. Analysts point to stronger assumptions around plozasiran in severe hypertriglyceridemia, the Madrigal partnership and the planned $215m priority review voucher purchase as key drivers of the revised valuation inputs.
Narratiefupdate • Aug 05
ARWR: Cardiometabolic RNAi Readouts In Severe Hypertriglyceridemia Will Drive Future Repricing
Arrowhead Pharmaceuticals' updated analyst price target of $126, up from $110, reflects analysts' higher modeled revenue growth and confidence in plozasiran following positive SHASTA-3 and SHASTA-4 Phase 3 data. Analyst Commentary Recent Street research on Arrowhead Pharmaceuticals shows a cluster of higher price targets and supportive commentary tied directly to the Phase 3 SHASTA-3 and SHASTA-4 results for plozasiran in severe hypertriglyceridemia.Seeking Alpha • Jul 22
Arrowhead Pharmaceuticals: Redemplo Meets High Expectations In SHTG Trials
Summary Arrowhead Pharmaceuticals reported positive phase 3 results for Redemplo, achieving 79-81% triglyceride reductions and significant acute pancreatitis risk reduction in severe hypertriglyceridemia. Redemplo demonstrates strong efficacy, quarterly dosing, and a favorable safety profile versus Ionis’ Tryngolza, positioning ARWR for leadership in the SHTG market. Tryngolza has a first-mover advantage and administration with an autoinjector versus the current prefilled syringe for Redemplo, but ARWR expects to have an autoinjector as well. I expect modest near-term sales from the small FCS market, with significant revenue potential upon SHTG launch following sNDA submission and likely approval by late 2027. Read the full article on Seeking Alpha
Narratiefupdate • Jul 21
ARWR: Upcoming SHASTA-3 And 4 Results Will Drive Bullish Repricing
Arrowhead Pharmaceuticals' updated fair value estimate has been lifted from $57.11 to $85.00 as analysts factor in higher Street price targets in the $95 to $98 range, supported by growing optimism around upcoming SHASTA-3/4 data for plozasiran and its potential in severe hypertriglyceridemia. Analyst Commentary Recent Street research on Arrowhead Pharmaceuticals centers on the upcoming SHASTA-3/4 data readout for plozasiran in severe hypertriglyceridemia, with several firms updating price targets as they reassess the company’s risk and opportunity profile.Narratiefupdate • Jul 07
ARWR: Cardiometabolic Progress And EU Approval Will Support But Not Eliminate SHTG Uncertainty
Arrowhead Pharmaceuticals' analyst price targets have moved higher into the mid $40s, with analysts pointing to updated assumptions on fair value, profitability and revenue trends as key reasons for the reset. Analyst Commentary Recent Street research on Arrowhead Pharmaceuticals points to a cluster of price target increases and rating changes that frame how analysts are thinking about valuation, execution risk, and growth potential at current levels in the mid $40s.Narratiefupdate • Jun 23
ARWR: Mixed Wave Data And Execution Risks Will Challenge Recent Rebound
Analysts have lifted their price expectations for Arrowhead Pharmaceuticals. The updated fair value estimate has moved from $42.57 to $57.11 as they factor in a slower anticipated revenue decline, a higher projected profit margin, and a slightly lower future P/E multiple.Analyse-artikel • Jun 20
Arrowhead Pharmaceuticals (ARWR) Stock Could Be 25.6% Undervalued After R And D Webinar Update
Arrowhead Pharmaceuticals (ARWR) recently outlined a Summer Series of R&D webinars focused on its cardiometabolic pipeline, alongside positive clinical updates and upcoming regulatory milestones that have drawn fresh attention to the stock. See our latest analysis for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals’ recent R&D webinar announcement and positive late May clinical readouts have coincided with strong momentum, including a 45.25% 3 month share price return and a very large 1...Narratiefupdate • Jun 08
ARWR: Cardiometabolic RNAi Readouts And Licensing Will Drive Future Repricing
Arrowhead Pharmaceuticals' updated analyst price target moves to $46, up from $35, as analysts factor in modestly higher long term growth and margin assumptions, along with a slightly lower discount rate, while keeping fair value unchanged at $110. Analyst Commentary Recent Street research around Arrowhead points to a constructive shift in tone, with a series of bullish analysts highlighting upside drivers tied to execution on the pipeline and the broader biotech backdrop.Narratiefupdate • May 25
ARWR: Cardiometabolic RNAi Data And Licensing Will Drive Future Repricing
Analysts have raised Arrowhead Pharmaceuticals' average price target by $11 to $46, citing a stronger sector backdrop, healthier biotech funding conditions, and reassessed growth and profitability assumptions. These are reflected in higher revenue growth expectations and a slightly higher future P/E multiple.Narratiefupdate • May 07
ARWR: Cardiometabolic RNAi Data And Licensing Progress Will Drive Future Repricing
Analysts have raised their Arrowhead Pharmaceuticals price target by $12 to $110, citing updated assumptions for a less severe revenue contraction, higher projected profit margins, and a lower forward P/E estimate in recent research. Analyst Commentary Recent Street research on Arrowhead Pharmaceuticals has reflected a mix of caution and renewed optimism, with several bullish analysts focusing on price target changes, upgrades, and the implications for valuation and execution risk.Narratiefupdate • Apr 21
ARWR: Wave Data Concerns Will Test Sustainability Of Recent Share Price Rebound
Arrowhead Pharmaceuticals' analyst price target has edged higher by about $0.26 to $42.57, with analysts pointing to updated views on profit margins and P/E assumptions following a mix of recent target raises and trims across the Street. Analyst Commentary Recent Street research on Arrowhead Pharmaceuticals reflects a split view, with some firms lifting targets sharply and others trimming expectations.Narratiefupdate • Apr 06
ARWR: RNAi Obesity And Cardiometabolic Data Will Drive Future Repricing
Narrative update on Arrowhead Pharmaceuticals The consensus analyst price target for Arrowhead Pharmaceuticals has been adjusted to $110. This reflects mixed recent research that pairs questions around Wave Life Sciences data with higher targets from several firms citing early obesity program results and the Redemplo launch.Narratiefupdate • Mar 23
ARWR: Obesity RNAi Data And Cardiometabolic Franchise Will Drive Future Repricing
Analysts have updated their views on Arrowhead Pharmaceuticals with a revised blended price target of $110. This reflects mixed shifts in assumptions around discount rate, revenue growth, profit margins and future P/E after recent obesity and cardiometabolic data, as well as the Redemplo launch.Narratiefupdate • Mar 09
ARWR: Obesity RNAi Data Will Test Sustainability Of Recent Share Price Rebound
Analysts have reduced their blended price target on Arrowhead Pharmaceuticals by about $2 to reflect a lower fair value estimate of $42.31. This incorporates more cautious assumptions on near term revenue growth and margins, even as recent research notes highlight supportive early obesity data and emerging cardiometabolic opportunities.Narratiefupdate • Feb 22
ARWR: Obesity And Cardiometabolic Pipeline Progress Will Drive Future Repricing
Narrative Update: Arrowhead Pharmaceuticals The updated analyst price framework for Arrowhead Pharmaceuticals keeps fair value at $110 while trimming implied future P/E assumptions, reflecting analysts' mixed but generally constructive reaction to recent obesity and cardiometabolic data and the Redemplo launch. Analyst Commentary Recent research updates on Arrowhead Pharmaceuticals cluster around two themes you should keep in mind: confidence in the obesity and cardiometabolic pipeline, and growing interest in the early commercial rollout of Redemplo.Analyse-artikel • Feb 12
Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Strong Earnings Are Of Good Quality
Arrowhead Pharmaceuticals, Inc.'s ( NASDAQ:ARWR ) earnings announcement last week was disappointing for investors...Narratiefupdate • Feb 08
ARWR: Obesity Pipeline Progress Will Drive Future Repricing In My View
Analysts raised their fair value estimate for Arrowhead Pharmaceuticals to $110 from $80 as they incorporate updated assumptions on Redemplo's launch, initial obesity pipeline data, and a lower projected future P/E multiple, while also reflecting slightly higher risk and more conservative expectations for revenue growth. Analyst Commentary Bullish analysts are leaning into Arrowhead's transition from a pure development story toward one with its first approved product and an emerging obesity pipeline, and they are adjusting their models to reflect both assets.Narratiefupdate • Jan 25
ARWR: Early Obesity RNAi Data Will Challenge Durability Of Recent Share Repricing
Narrative update on Arrowhead Pharmaceuticals The updated analyst price target for Arrowhead Pharmaceuticals shifts to reflect a fair value of $44.02. Analysts point to Redemplo's approval and launch, early data from the ARO INHBE and ARO ALK7 obesity programs, and increased confidence in the pipeline as key factors in their revised outlook.Narratiefupdate • Jan 11
ARWR: Obesity RNAi Data Will Test Sustainability Of Recent Share Repricing
Arrowhead Pharmaceuticals' analyst fair value estimate moved from $17.00 to about $44.94, as analysts cited early obesity trial data for ARO INHBE and ARO ALK7, validation of the TRiM RNAi platform, and the first FDA approval of Redemplo as key reasons for higher price targets in the US$80 range. Analyst Commentary Street research around Arrowhead has tilted more constructive around the obesity franchise, with multiple firms lifting their fair value estimates into the US$80 range after the initial ARO INHBE and ARO ALK7 data.Narratiefupdate • Dec 18
ARWR: Upcoming SHTG Readouts Will Temper Optimism Despite Recent Cardiometabolic Progress
Analysts have raised their price targets on Arrowhead Pharmaceuticals by roughly $6 to the mid $40s to low $60s range, citing the FDA approval of Redemplo, a strengthened commercial outlook in familial chylomicronemia syndrome and sHTG, and underappreciated long term cost and margin advantages. Analyst Commentary Bullish analysts view Redemplo's FCS approval as a key de-risking event that supports higher valuation multiples and justifies recent price target increases into the high $40s to low $60s range.Narratiefupdate • Dec 04
ARWR: Upcoming SHTG Data Will Likely Undermine Optimistic Cardiometabolic Expectations
Analysts have nudged their average price target on Arrowhead Pharmaceuticals higher to about $58 from $55, citing the FDA approval of Redemplo, expectations for a broader sHTG label, and underappreciated long term cost and margin advantages. Analyst Commentary Research coverage following the Redemplo approval has generally tilted positive, with several firms lifting their price targets and highlighting both the commercial opportunity in sHTG and Arrowhead's long term margin profile.Analyse-artikel • Dec 02
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Catapults 33% Though Its Price And Business Still Lag The Industry
Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) shares have continued their recent momentum with a 33% gain in the last...Narratiefupdate • Nov 20
ARWR: FDA Milestone Will Drive Cost Advantage In Cardiometabolic Markets
Analysts have raised Arrowhead Pharmaceuticals' fair value estimate from $47.50 to $55.00 per share after the FDA approved Redemplo and expressed increased confidence in the company's commercial execution and cost advantages. Analyst Commentary Following the recent FDA approval of Redemplo, analysts have provided updated perspectives on Arrowhead Pharmaceuticals' valuation and prospects.Narratiefupdate • Nov 06
ARWR: Expect Cost Efficiency To Drive Competitive Advantage In Upcoming Metabolic Trials
Analysts have significantly raised their price target for Arrowhead Pharmaceuticals, increasing it from $38 to $61 per share. They cite structural cost advantages and an underappreciated long-term gross margin potential as key factors for this change.Narratiefupdate • Oct 22
Analysts Boost Arrowhead Pharmaceuticals Price Target Amid Cost Advantages and Strategic Partnerships
Arrowhead Pharmaceuticals' analyst price target has been raised from $45 to $47.50 per share. Analysts highlight the company's structural cost advantages and improved margin outlook.Analyse-artikel • Oct 07
What Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) 29% Share Price Gain Is Not Telling You
Despite an already strong run, Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) shares have been powering on, with a...Narratiefupdate • Oct 05
RNAi Pipeline Will Unlock Emerging Markets Despite Regulatory Risks
Analysts have slightly lowered their price target for Arrowhead Pharmaceuticals from $46.15 to $45.00, citing ongoing concerns following recent strategic divestitures by partners and modest shifts in the company's projected financials. Analyst Commentary Recent analyst research provides a mixed outlook for Arrowhead Pharmaceuticals following notable events involving partner Sarepta Therapeutics.Narratiefupdate • Sep 08
RNAi Pipeline Will Unlock Emerging Markets Despite Regulatory Risks
The consensus price target for Arrowhead Pharmaceuticals has increased modestly as its Future P/E has risen and Net Profit Margin has declined, resulting in a new analyst fair value of $46.15. What's in the News Arrowhead Pharmaceuticals announced a major global licensing and collaboration agreement with Novartis for ARO-SNCA, its preclinical siRNA therapy for synucleinopathies such as Parkinson’s Disease; the deal includes a $200 million upfront payment to Arrowhead, potential milestones up to $2 billion, and future royalties, with closing expected in the second half of 2025 (Key Developments).Analyse-artikel • Aug 21
Improved Revenues Required Before Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock's 37% Jump Looks Justified
The Arrowhead Pharmaceuticals, Inc. ( NASDAQ:ARWR ) share price has done very well over the last month, posting an...Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 9/30/2028 | 707 | -369 | -605 | -380 | 8 |
| 9/30/2027 | 339 | -655 | -701 | -586 | 13 |
| 9/30/2026 | 463 | -504 | -550 | -404 | 12 |
| 6/30/2026 | 669 | -320 | -75 | -59 | N/A |
| 3/31/2026 | 622 | -301 | -51 | -36 | N/A |
| 12/31/2025 | 1,091 | 202 | 322 | 339 | N/A |
| 9/30/2025 | 829 | -2 | 157 | 180 | N/A |
| 6/30/2025 | 573 | -148 | -18 | 22 | N/A |
| 3/31/2025 | 545 | -144 | 10 | 61 | N/A |
| 12/31/2024 | 3 | -640 | -572 | -491 | N/A |
| 9/30/2024 | 4 | -599 | -604 | -463 | N/A |
| 6/30/2024 | 20 | -539 | -533 | -352 | N/A |
| 3/31/2024 | 35 | -471 | -470 | -257 | N/A |
| 12/31/2023 | 182 | -297 | -403 | -196 | N/A |
| 9/30/2023 | 241 | -205 | -331 | -154 | N/A |
| 6/30/2023 | 256 | -181 | -342 | -197 | N/A |
| 3/31/2023 | 273 | -150 | -353 | -245 | N/A |
| 12/31/2022 | 278 | -155 | -236 | -150 | N/A |
| 9/30/2022 | 243 | -176 | -189 | -136 | N/A |
| 6/30/2022 | 250 | -154 | -120 | -91 | N/A |
| 3/31/2022 | 263 | -112 | -75 | -52 | N/A |
| 12/31/2021 | 144 | -183 | 124 | 149 | N/A |
| 9/30/2021 | 138 | -141 | 148 | 171 | N/A |
| 6/30/2021 | 108 | -126 | 167 | 184 | N/A |
| 3/31/2021 | 89 | -110 | 165 | 181 | N/A |
| 12/31/2020 | 80 | -103 | -123 | -111 | N/A |
| 9/30/2020 | 88 | -85 | -108 | -96 | N/A |
| 6/30/2020 | 124 | -24 | -89 | -71 | N/A |
| 3/31/2020 | 139 | 10 | N/A | -27 | N/A |
| 12/31/2019 | 164 | 53 | N/A | -19 | N/A |
| 9/30/2019 | 169 | 68 | N/A | 173 | N/A |
| 6/30/2019 | 137 | 46 | N/A | 157 | N/A |
| 3/31/2019 | 95 | 10 | N/A | 132 | N/A |
| 12/31/2018 | 47 | -29 | N/A | 136 | N/A |
| 9/30/2018 | 16 | -54 | N/A | -47 | N/A |
| 6/30/2018 | 14 | -54 | N/A | -54 | N/A |
| 3/31/2018 | 22 | -44 | N/A | -50 | N/A |
| 12/31/2017 | 31 | -35 | N/A | -49 | N/A |
| 9/30/2017 | 31 | -34 | N/A | -24 | N/A |
| 6/30/2017 | 23 | -46 | N/A | -25 | N/A |
| 3/31/2017 | 13 | -60 | N/A | -33 | N/A |
| 12/31/2016 | 4 | -75 | N/A | -33 | N/A |
| 9/30/2016 | 0 | -82 | N/A | -64 | N/A |
| 6/30/2016 | 0 | -84 | N/A | -66 | N/A |
| 3/31/2016 | 0 | -81 | N/A | -61 | N/A |
| 12/31/2015 | 0 | -89 | N/A | -63 | N/A |
| 9/30/2015 | 0 | -92 | N/A | -66 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat ARWR de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat ARWR de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat ARWR de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van ARWR ( 29.7% per jaar) zal naar verwachting sneller groeien dan de markt US ( 12.9% per jaar).
Hoge groei-inkomsten: De omzet van ARWR ( 29.7% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Er wordt voorspeld dat ARWR binnen 3 jaar verliesgevend zal zijn.
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/08/19 09:11 |
| Aandelenkoers aan het einde van de dag | 2026/08/19 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/09/30 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Arrowhead Pharmaceuticals, Inc. wordt gevolgd door 29 analisten. 13 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Ying Huang | Barclays |
| William Pickering | Bernstein |
| Jason Matthew Gerberry | BofA Global Research |